BioNTech SE (NASDAQ:BNTX) Shares Purchased by ProShare Advisors LLC

Posted by on Apr 26th, 2023

ProShare Advisors LLC increased its holdings in shares of BioNTech SE (NASDAQ:BNTX – Get Rating) by 2.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 7,606 shares of the company’s stock after acquiring an additional 193 shares during the period. ProShare Advisors LLC’s holdings in BioNTech were worth $1,143,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of BNTX. Temasek Holdings Private Ltd grew its position in shares of BioNTech by 714.3% during the 3rd quarter. Temasek Holdings Private Ltd now owns 4,378,022 shares of the company’s stock valued at $590,508,000 after acquiring an additional 3,840,388 shares during the period. Artisan Partners Limited Partnership grew its position in shares of BioNTech by 200.7% during the 3rd quarter. Artisan Partners Limited Partnership now owns 2,228,913 shares of the company’s stock valued at $300,636,000 after acquiring an additional 1,487,687 shares during the period. Baillie Gifford & Co. grew its position in shares of BioNTech by 6.5% during the 4th quarter. Baillie Gifford & Co. now owns 7,718,123 shares of the company’s stock valued at $1,159,416,000 after acquiring an additional 473,051 shares during the period. BlackRock Inc. grew its position in shares of BioNTech by 25.9% during the 1st quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock valued at $274,768,000 after acquiring an additional 331,101 shares during the period. Finally, Flossbach Von Storch AG grew its position in shares of BioNTech by 9.8% during the 3rd quarter. Flossbach Von Storch AG now owns 3,364,564 shares of the company’s stock valued at $453,812,000 after acquiring an additional 299,414 shares during the period. 15.29% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on BNTX shares. Jefferies Financial Group set a $145.00 target price on BioNTech in a research report on Tuesday, March 28th. TD Cowen lowered their price objective on BioNTech from $145.00 to $130.00 and set a “market perform” rating on the stock in a report on Tuesday, March 28th. Bank of America lowered their price objective on BioNTech from $239.00 to $194.00 and set a “buy” rating on the stock in a report on Monday, March 27th. UBS Group lowered their price objective on BioNTech from $168.00 to $153.00 and set a “neutral” rating on the stock in a report on Friday, March 31st. Finally, TheStreet cut BioNTech from a “b-” rating to a “c+” rating in a report on Monday, March 27th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, BioNTech has a consensus rating of “Hold” and an average price target of $177.50.

BioNTech Trading Down 2.3 %

Shares of BioNTech stock opened at $114.25 on Wednesday. The stock has a market cap of $27.79 billion, a P/E ratio of 2.87 and a beta of 0.22. The stock’s 50 day simple moving average is $128.81 and its 200-day simple moving average is $143.72. BioNTech SE has a 1-year low of $111.53 and a 1-year high of $188.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.43 and a quick ratio of 7.28.

BioNTech (NASDAQ:BNTX – Get Rating) last issued its earnings results on Monday, March 27th. The company reported $9.26 earnings per share for the quarter, topping the consensus estimate of $8.04 by $1.22. The business had revenue of $4.28 billion for the quarter, compared to analysts’ expectations of $3.87 billion. BioNTech had a return on equity of 53.36% and a net margin of 54.61%. The business’s revenue for the quarter was down 22.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $13.93 EPS. Analysts predict that BioNTech SE will post 4.85 EPS for the current fiscal year.

About BioNTech

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Further Reading

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE (NASDAQ:BNTX – Get Rating).

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.